Sector News

Bayer eyes new corporate structure by Jan 2016

February 13, 2015
Life sciences
(Reuters) – German healthcare group Bayer has started working on a new corporate set-up for the life-science businesses that will remain when its plastics division is split off, aiming for a new structure at the beginning of next year.
 
Employees were informed on Wednesday that a team had been set up to map out the new structure, which will not entail job cuts, a spokesman said on Thursday.
 
“We expect the number of jobs to be stable worldwide and in Germany over the next few years,” he added.
 
Bayer, whose products include cancer drugs, birth control pills, veterinary drugs, pesticides and transparent plastics, unveiled plans in September to list its plastics business on the stock market to focus on its more profitable life-science businesses.
 
It said at the time it was eyeing a spin-off or initial public offering of the MaterialScience unit within 12-18 months.
 
Its three main divisions HealthCare, CropScience and MaterialScience each have largely autonomous management teams but the company has recently stressed the synergies to be gained in the research into human, animal and plant health. (Reporting by Ludwig Burger; Editing by Mark Potter)

comments closed

Related News

March 15, 2024

Novo’s obesity superstar Wegovy wins FDA nod to cut cardio risks in key label expansion

Life sciences

Novo Nordisk’s fast-growing weight loss med Wegovy just added a new cardiovascular FDA approval to its label, likely enabling the med’s superstar status to reach new levels. The med is now the first weight loss treatment to score an FDA nod to reduce the risk of cardiovascular death, heart attack and stroke in adult patients with cardiovascular disease who have obesity or are overweight.

March 15, 2024

Galderma sets price range for supersized $2.6bn IPO in Europe

Life sciences

Galderma has announced a price range of CHF 49 to CHF 53 ($55.8 to $60.3) per share for floatation on the SIX Swiss Exchange. The Swiss skincare company, which revealed its intention to conduct an initial public offering (IPO) earlier in March, will have 40,453,467 new shares available. The offering also consists of 276,909 existing shares.

March 15, 2024

After transformation under new CEO, Leo Pharma touts innovation model and financial progress

Life sciences

Taking over as CEO for an aging company in dire financial straits and in need of a slim-down was a challenging assignment for Christophe Bourdon. But under Bourdon’s watch, Leo Pharma is taking steps toward a rebound. Last month, the 115-year-old Danish private company reported that it cut its operating costs by 14% in 2023 while increasing its revenues by 7%.

How can we help you?

We're easy to reach